Seeking Alpha

Rigel Pharmaceuticals (RIGL +4.9%) kicks up a gain after Citigroup upgrades shares to a Buy...

Rigel Pharmaceuticals (RIGL +4.9%) kicks up a gain after Citigroup upgrades shares to a Buy rating from Neutral. SA author Stephen Simpson notes that if the firm strikes some success with studies of drugs in its pipeline it may make a juicy acquisition candidate for AstraZeneca.
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs